September 16, 2024

Figure S1 from Loss of LGR5 through therapy-induced downregulation or gene ablation is associated with resistance and enhanced MET-STAT3 signaling in colorectal cancer cells

Key Points

Key points are not available for this paper at this time.

Abstract

shows effects of chemotherapies and ADC on LGR5 protein and mRNA expression and LGR5 knockdown effects on clonogenicity, signaling pathways, and expression of STAT3 target genes.

Demander à l'IA

Bookmark

Cite This Study

Posey et al. (Mon,) studied this question.

synapsesocial.com/papers/68e586c1b6db6435875238d4 https://doi.org/https://doi.org/10.1158/1535-7163.27035770.v1

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Figure S3 from Loss of LGR5 through therapy-induced downregulation or gene ablation is associated with resistance and enhanced MET-STAT3 signaling in colorectal cancer cells2024
2Figure S2 from Loss of LGR5 through therapy-induced downregulation or gene ablation is associated with resistance and enhanced MET-STAT3 signaling in colorectal cancer cells2024
3Figure S5 from Loss of LGR5 through therapy-induced downregulation or gene ablation is associated with resistance and enhanced MET-STAT3 signaling in colorectal cancer cells2024
4Figure S6 from Loss of LGR5 through therapy-induced downregulation or gene ablation is associated with resistance and enhanced MET-STAT3 signaling in colorectal cancer cells2024
5Figure S4 from Loss of LGR5 through therapy-induced downregulation or gene ablation is associated with resistance and enhanced MET-STAT3 signaling in colorectal cancer cells2024

Demander à l'IA

Bookmark